LY
Lyra Therapeutics, Inc.
LYRA · OTC
$0.03 -85.00% (-$0.17)
1M -85.00%
Market Cap $355.0K
P/E Ratio -
Div. Yield -
ROE -
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.89x
EV/EBITDA N/A
P/B N/A
Growth
58 /100
Stable Book val. growth 6.28%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 7,266.08%
Op. margin 7,794.47%
FCF margin 7,280.15%
Quality
0 /100
Poor ROA 80.09%
Asset turnover 0.01x
ROIC 98.82%
Debt
85 /100
Low Current ratio 1.71x
Int. coverage N/A
Net debt/EBITDA N/A
Stability
59 /100
Moderate EPS volatility 39.67%
Profitable years 0
Beta 0.71x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o LYRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carmichael S. Roberts Jr.
Employees
27
Headquarters
Watertown
Prihajajoči dogodki
17 NOV.
Earnings
Upcoming earnings report